|PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations|
F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ...
Journal of clinical oncology 30 (8), 777, 2012
|Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer|
H Liang, LWT Cheung, J Li, Z Ju, S Yu, K Stemke-Hale, T Dogruluk, Y Lu, ...
Genome research 22 (11), 2120-2129, 2012
|Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome|
SN Westin, RA Lacour, DL Urbauer, R Luthra, DC Bodurka, KH Lu, ...
Journal of Clinical Oncology 26 (36), 5965, 2008
|AKT inhibition in solid tumors with AKT1 mutations|
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
|A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer|
PT Soliman, SN Westin, S Dioun, CC Sun, E Euscher, MF Munsell, ...
Gynecologic oncology 146 (2), 234-239, 2017
|Clinical cancer advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology|
J Heymach, L Krilov, A Alberg, N Baxter, SM Chang, RB Corcoran, ...
Journal of Clinical Oncology 36 (10), 1020-1044, 2018
|Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade …|
UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ...
Annals of Oncology 28 (3), 512-518, 2017
|Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology|
PT Soliman, M Frumovitz, CC Sun, R Dos Reis, KM Schmeler, AM Nick, ...
Gynecologic oncology 123 (2), 333-336, 2011
|Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology–RTOG 1203|
AH Klopp, AR Yeung, S Deshmukh, KM Gil, L Wenzel, SN Westin, ...
Journal of Clinical Oncology 36 (24), 2538, 2018
|Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers|
C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ...
Science translational medicine 9 (392), 2017
|Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device|
N Pal, RR Broaddus, DL Urbauer, N Balakrishnan, A Milbourne, ...
Obstetrics and gynecology 131 (1), 109, 2018
|Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer|
GM Rauch, H Kaur, H Choi, RD Ernst, AH Klopp, P Boonsirikamchai, ...
Radiographics 34 (4), 1082-1098, 2014
|Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial|
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
|Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy|
Y Fang, DJ McGrail, C Sun, M Labrie, X Chen, D Zhang, Z Ju, CP Vellano, ...
Cancer cell 35 (6), 851-867. e7, 2019
|Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence|
A Carroll, PT Ramirez, SN Westin, PT Soliman, MF Munsell, AM Nick, ...
Gynecologic oncology 135 (3), 455-461, 2014
|A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH …|
I Brana, R Berger, T Golan, P Haluska, J Edenfield, J Fiorica, ...
British journal of cancer 111 (10), 1932-1944, 2014
|Overall survival after pelvic exenteration for gynecologic malignancy|
SN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ...
Gynecologic oncology 134 (3), 546-551, 2014
|A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers|
U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ...
Clinical Cancer Research 24 (9), 2050-2059, 2018
|What women with ovarian cancer think and know about genetic testing|
RA Lacour, MS Daniels, SN Westin, LA Meyer, CC Burke, KA Burns, ...
Gynecologic oncology 111 (1), 132-136, 2008
|Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer|
ND Fleming, M Frumovitz, KM Schmeler, R Dos Reis, MF Munsell, PJ Eifel, ...
Gynecologic oncology 136 (1), 48-53, 2015